Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital

Key Points

• Analysts at Lifesci Capital have raised Zymeworks' Q1 2026 earnings per share estimate to $0.48, compared to a previous estimate of $0.47.
• The company's current full-year consensus estimate stands at a loss of ($1.39) per share.
• Zymeworks has a market capitalization of $1.24 billion and its stock has a 52-week trading range of $9.03 to $17.70.

Zymeworks Inc. (NYSE:ZYME - Free Report) - Research analysts at Lifesci Capital raised their Q1 2026 earnings per share estimates for Zymeworks in a research report issued on Monday, October 6th. Lifesci Capital analyst C. Zhu now anticipates that the company will post earnings of $0.48 per share for the quarter, up from their previous estimate of $0.47. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share.

Several other research analysts also recently commented on the company. HC Wainwright restated a "neutral" rating and issued a $13.00 target price on shares of Zymeworks in a research note on Thursday, July 3rd. Citigroup raised their price target on Zymeworks from $19.00 to $22.00 and gave the company a "buy" rating in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Zymeworks has an average rating of "Moderate Buy" and a consensus price target of $21.43.

Zymeworks Stock Performance

ZYME stock opened at $16.50 on Wednesday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -11.00 and a beta of 1.51. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $17.70. The stock has a fifty day moving average of $14.88 and a 200-day moving average of $13.17.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.55. The company had revenue of $48.73 million for the quarter, compared to analyst estimates of $17.18 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.Zymeworks's revenue for the quarter was up 153.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.49) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in shares of Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company's stock valued at $62,000 after buying an additional 1,131 shares during the period. Janney Montgomery Scott LLC boosted its holdings in Zymeworks by 12.7% in the first quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company's stock valued at $138,000 after purchasing an additional 1,300 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company's stock valued at $386,000 after buying an additional 1,427 shares in the last quarter. Picton Mahoney Asset Management raised its stake in Zymeworks by 0.7% during the first quarter. Picton Mahoney Asset Management now owns 208,029 shares of the company's stock valued at $2,477,000 after buying an additional 1,460 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in Zymeworks by 6.7% during the second quarter. Bank of Montreal Can now owns 27,642 shares of the company's stock valued at $347,000 after buying an additional 1,730 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company's stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.